Chinook Therapeutics, Inc. financial data

Industry
Pharmaceutical Preparations
Location
400 Fairview Avenue North, Suite 900, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
ADURO BIOTECH, INC. (to 10/15/2020), ADURO BIOTECH (to 4/22/2011)
Latest financial report
10-Q - Q2 2023 - Aug 7, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 719 % -18.5%
Debt-to-equity 30.3 % +19%
Return On Equity -58.3 % -161%
Return On Assets -44.7 % -151%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.8M shares +14.2%
Common Stock, Shares, Outstanding 67.1M shares +6.69%
Entity Public Float 896M USD +94.8%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 71.6M shares +15.5%
Weighted Average Number of Shares Outstanding, Diluted 71.6M shares +15.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 5.85M USD -89.2%
Research and Development Expense 194M USD +84.9%
General and Administrative Expense 44.3M USD +42.3%
Operating Income (Loss) -252M USD -192%
Income Tax Expense (Benefit) 4.34M USD +53.2%
Net Income (Loss) Attributable to Parent -246M USD -166%
Earnings Per Share, Basic -3.56 USD/shares -54.1%
Earnings Per Share, Diluted -3.56 USD/shares -54.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 127M USD -12.9%
Marketable Securities, Current 170M USD -21.5%
Assets, Current 305M USD -17.8%
Property, Plant and Equipment, Net 16.2M USD -7.23%
Operating Lease, Right-of-Use Asset 42.9M USD -18%
Intangible Assets, Net (Excluding Goodwill) 60M USD -2.8%
Goodwill 117K USD 0%
Other Assets, Noncurrent 14.2M USD +101%
Assets 489M USD -18.7%
Accounts Payable, Current 16.4M USD +233%
Liabilities, Current 52.5M USD +78%
Deferred Income Tax Liabilities, Net 5.08M USD +591%
Operating Lease, Liability, Noncurrent 29.7M USD -20%
Liabilities 132M USD +40%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.33M USD +47.6%
Retained Earnings (Accumulated Deficit) -547M USD -81.6%
Stockholders' Equity Attributable to Parent 357M USD -29.6%
Liabilities and Equity 489M USD -18.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -50.7M USD -105%
Net Cash Provided by (Used in) Financing Activities 21.3M USD +1106%
Net Cash Provided by (Used in) Investing Activities 32.4M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 67.1M shares +6.69%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.06M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 129M USD -12.7%
Deferred Tax Assets, Valuation Allowance 98.7M USD +65.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 127M USD +66.2%
Operating Lease, Liability 34M USD -18.8%
Payments to Acquire Property, Plant, and Equipment 927K USD +148%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -244M USD -157%
Lessee, Operating Lease, Liability, to be Paid 42.2M USD -21.1%
Property, Plant and Equipment, Gross 25.8M USD +11.7%
Operating Lease, Liability, Current 4.27M USD -9.21%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.71M USD -14.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.59M USD -14.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.19M USD -29.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.71M USD -16.3%
Deferred Tax Assets, Operating Loss Carryforwards 75.6M USD +40.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.48M USD -9.42%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 1.73M USD +1.59%
Deferred Tax Assets, Net of Valuation Allowance 28M USD +69.7%
Share-based Payment Arrangement, Expense 28.1M USD +78.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%